SG Americas Securities LLC decreased its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 13.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,870,302 shares of the company's stock after selling 431,679 shares during the period. SG Americas Securities LLC owned approximately 0.78% of Bausch Health Companies worth $18,571,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Toronto Dominion Bank boosted its stake in shares of Bausch Health Companies by 1.0% in the 4th quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock valued at $1,350,000 after purchasing an additional 1,712 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Bausch Health Companies by 7.9% in the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock worth $209,000 after purchasing an additional 1,896 shares in the last quarter. American Century Companies Inc. lifted its stake in Bausch Health Companies by 10.6% during the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock valued at $220,000 after acquiring an additional 2,600 shares during the period. Blair William & Co. IL lifted its stake in shares of Bausch Health Companies by 3.2% in the 4th quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock worth $683,000 after purchasing an additional 2,622 shares during the period. Finally, Kendall Capital Management increased its holdings in Bausch Health Companies by 43.4% in the 4th quarter. Kendall Capital Management now owns 17,995 shares of the company's stock worth $145,000 after acquiring an additional 5,445 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.
Analyst Upgrades and Downgrades
BHC has been the subject of a number of research reports. Wall Street Zen downgraded Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. Royal Bank of Canada boosted their price target on Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $7.42.
Get Our Latest Stock Analysis on BHC
Bausch Health Companies Trading Up 3.9%
Shares of BHC stock traded up $0.21 during mid-day trading on Thursday, reaching $5.54. The stock had a trading volume of 4,208,746 shares, compared to its average volume of 2,574,755. The company has a market cap of $2.05 billion, a P/E ratio of -46.16, a price-to-earnings-growth ratio of 0.37 and a beta of 0.28. The business has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $6.44. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $9.85.
Insider Transactions at Bausch Health Companies
In other news, Director John Paulson bought 1,029,098 shares of the firm's stock in a transaction on Wednesday, June 11th. The stock was purchased at an average price of $5.24 per share, for a total transaction of $5,392,473.52. Following the transaction, the director now owns 28,222,267 shares in the company, valued at approximately $147,884,679.08. This trade represents a 3.78% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders acquired 2,788,608 shares of company stock valued at $14,700,257 over the last 90 days. Corporate insiders own 8.05% of the company's stock.
Bausch Health Companies Company Profile
(
Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Articles
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
